- Home
- CAPR vs AKBA Comparison
CAPR vs AKBA Comparison
Compare CAPR & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- AKBA
- Stock Information
- Founded
- CAPR 2005
- AKBA 2007
- Country
- CAPR United States
- AKBA United States
- Employees
- CAPR N/A
- AKBA N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- CAPR Health Care
- AKBA Health Care
- Exchange
- CAPR Nasdaq
- AKBA Nasdaq
- Market Cap
- CAPR 332.5M
- AKBA 336.2M
- IPO Year
- CAPR N/A
- AKBA 2014
- Fundamental
- Price
- CAPR $17.79
- AKBA $1.82
- Analyst Decision
- CAPR Strong Buy
- AKBA Strong Buy
- Analyst Count
- CAPR 7
- AKBA 2
- Target Price
- CAPR $39.29
- AKBA $5.75
- AVG Volume (30 Days)
- CAPR 1.1M
- AKBA 2.4M
- Earning Date
- CAPR 11-13-2024
- AKBA 11-07-2024
- Dividend Yield
- CAPR N/A
- AKBA N/A
- EPS Growth
- CAPR N/A
- AKBA N/A
- EPS
- CAPR N/A
- AKBA N/A
- Revenue
- CAPR $23,228,045.00
- AKBA $169,879,000.00
- Revenue This Year
- CAPR N/A
- AKBA N/A
- Revenue Next Year
- CAPR $135.53
- AKBA $6.13
- P/E Ratio
- CAPR N/A
- AKBA N/A
- Revenue Growth
- CAPR 65.33
- AKBA N/A
- 52 Week Low
- CAPR $2.90
- AKBA $0.80
- 52 Week High
- CAPR $23.40
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- CAPR 47.77
- AKBA 56.59
- Support Level
- CAPR $17.21
- AKBA $1.76
- Resistance Level
- CAPR $19.47
- AKBA $2.02
- Average True Range (ATR)
- CAPR 1.64
- AKBA 0.11
- MACD
- CAPR -0.38
- AKBA -0.02
- Stochastic Oscillator
- CAPR 28.33
- AKBA 40.00
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.